Home
Approach
Product
About
News
Contact
News
Login
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
Next
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Journal of Clinical Oncology: IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
ASCO: Automated imaging-based stratification of early-stage lung cancer patients using deep learning applied to pretreatment CT scans
ASCO: Deep learning applied to pretreatment CTs provides personalized prognostic insight for lung cancer patients
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Axios: Clinical trial startup seeds $6M to speed research
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
.png)
.jpg)
.png)
.png)
.png)
.png)
.png)
